The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 22, 2022
Filed:
Aug. 29, 2019
Applicant:
Bristol-myers Squibb Company, Princeton, NJ (US);
Inventors:
James Aaron Balog, Lambertville, NJ (US);
Steven P. Seitz, Swarthmore, PA (US);
Susheel Jethanand Nara, Mumbai, IN;
Saumya Roy, Bangalore, IN;
Srinivasan Thangathirupathy, Hosur, IN;
Soodamani Thangavel, Krishnagiri, IN;
Srinivas Cheruku, Bangalore, IN;
Assignee:
Bristol-Myers Squibb Company, Princeton, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 31/17 (2006.01); A61K 31/44 (2006.01); A61K 31/50 (2006.01); A61K 31/136 (2006.01); A61K 31/275 (2006.01); A61K 31/351 (2006.01); A61K 31/428 (2006.01); A61K 31/4965 (2006.01); A61K 31/505 (2006.01); A61K 31/5375 (2006.01); A61K 31/5377 (2006.01); C07C 211/54 (2006.01); C07C 229/42 (2006.01); C07C 255/58 (2006.01); C07C 275/42 (2006.01); C07D 213/90 (2006.01); C07D 237/22 (2006.01); C07D 239/42 (2006.01); C07D 239/47 (2006.01); C07D 241/18 (2006.01); C07D 265/30 (2006.01); C07D 277/64 (2006.01); C07D 295/03 (2006.01); C07D 407/12 (2006.01); C07D 413/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/136 (2013.01); A61K 31/17 (2013.01); A61K 31/275 (2013.01); A61K 31/428 (2013.01); A61K 31/4965 (2013.01); A61K 31/505 (2013.01); A61K 31/5375 (2013.01); C07C 211/54 (2013.01); C07C 275/42 (2013.01); C07D 239/42 (2013.01); C07D 239/47 (2013.01); C07D 241/18 (2013.01); C07D 277/64 (2013.01); C07D 295/03 (2013.01); C07D 413/12 (2013.01);
Abstract
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.